Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
February 2, 2023iScienceOpen Access

A prime-boost immunization with the PHH-1V recombinant protein vaccine conferred 100% efficacy in preventing mortality in SARS-CoV-2 infected K18-hACE2 mice.

View Full Paper
Ask AI
Bookmark
Share

Why the study?

SARS-CoV-2 variants are continuously evolving, making the development of new accessible COVID-19 vaccines essential to mitigate the pandemic.

Does prime-boost immunisation with PHH-1V induce immunity and prevent mortality in SARS-CoV-2 infected mice?

Population

BALB/c and K18-hACE2 mice

Comparison

Prime-boost immunisation with PHH-1V vaccine candidate

Design

Preclinical animal study

Key result

A prime-boost immunization with the PHH-1V recombinant protein vaccine conferred 100% efficacy in preventing mortality in SARS-CoV-2 infected K18-hACE2 mice.

Authors

ABAntonio BarreiroAPAntoni PrenafetaGBG. Bech-Sàbat

Discussion

Loading...

Member takes

Overview

Supports PHH-1V advancement; leaves open human efficacy against variants.

Structured PICO

Does prime-boost immunisation with PHH-1V induce immunity and prevent mortality in SARS-CoV-2 infected mice?

P
Population
Preclinical study in BALB/c and K18-hACE2 mice evaluating a recombinant RBD fusion heterodimer COVID-19 vaccine.
I
Intervention
Prime-boost immunisation with PHH-1V (an RBD-based recombinant protein vaccine consisting of an RBD fusion heterodimer comprising the B.1.351 and B.1.1.7 SARS-CoV-2 variants formulated in SQBA adjuvant)
O
Outcome
CD4+ and CD8+ T cell response, RBD-binding antibodies with neutralizing activity, mortality, and infection in lower respiratory airwayssurrogate

Main Result

Effect estimate: 100% efficacy

The PHH-1V recombinant protein vaccine candidate induces robust immune responses and provides 100% protection against mortality in SARS-CoV-2 infected mice.

Cite This Study

Barreiro et al. (2023) studied COVID-19. PHH-1V (RBD-based recombinant protein vaccine) was evaluated on Mortality in SARS-CoV-2 infected K18-hACE2 mice (100% efficacy). A prime-boost immunization with the PHH-1V recombinant protein vaccine conferred 100% efficacy in preventing mortality in SARS-CoV-2 infected K18-hACE2 mice.

synapsesocial.com/papers/6a98c5801c4dac29babd3fcchttps://doi.org/10.1016/j.isci.2023.106126
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Preclinical assessment of a recombinant RBD-Fc fusion protein as SARS-CoV-2 candidate vaccine2024 · 10 citations
  2. 2An RBD-Fc mucosal vaccine provides variant-proof protection against SARS-CoV-2 in mice and hamsters2025 · 11 citations
  3. 3Recombinant RBD-based subunit vaccines incorporating high-frequency mutation sites elicit cross-immunity and robust protection against SARS-CoV-22026
  4. 4Enhanced Immunogenicity and Protective Effects against SARS-CoV-2 Following Immunization with a Recombinant RBD-IgG Chimeric Protein2024 · 3 citations
  5. 5Immunogenicity evaluation of an Alum-adjuvanted recombinant prefusion RBD-Fd SARS-CoV-2 protein subunit produced in Glycoengineered Pichia pastoris2025